T
Takeshi Yamashita
Researcher at Cardiovascular Institute of the South
Publications - 309
Citations - 5645
Takeshi Yamashita is an academic researcher from Cardiovascular Institute of the South. The author has contributed to research in topics: Atrial fibrillation & Medicine. The author has an hindex of 33, co-authored 261 publications receiving 4543 citations.
Papers
More filters
Journal ArticleDOI
Prevalence of atrial fibrillation in the general population of Japan: an analysis based on periodic health examination.
Hiroshi Inoue,Akira Fujiki,Hideki Origasa,Satoshi Ogawa,Ken Okumura,Isao Kubota,Yoshifusa Aizawa,Takeshi Yamashita,Hirotsugu Atarashi,Minoru Horie,Tohru Ohe,Yoshinori Doi,Akihiko Shimizu,Akiko Chishaki,Tetsunori Saikawa,Katsusuke Yano,Akira Kitabatake,Hideo Mitamura,Itsuo Kodama,Shiro Kamakura +19 more
TL;DR: The prevalence of AF increased in Japan as the population aged, as in Western countries, and the overall prevalence in Japan is approximately two-thirds of that in the USA.
Journal Article
Guidelines for Pharmacotherapy of Atrial Fibrillation (JCS 2008) : Digest Version
Satoshi Ogawa,Yoshifusa Aizawa,Hirotsugu Atarashi,Hiroshi Inoue,Shiro Kamakura,Yukihiro Koretsune,Koichiro Kumagai,Hideo Mitamura,Ken Okumura,Kaoru Sugi,Takeshi Yamashita,Masahiro Yasaka,Kazumasa Hiejima,Itsuo Kodama,Tohru Ohe,Katsusuke Yano +15 more
TL;DR: The guidelines for pharmacotherapy of arrhythmia in Japan are based on the concepts of the Sicilian Gambit, which highlight evidence-based recommendations, though the logical rationales supplied for selection of antiarrhythmic drugs are limited.
Journal ArticleDOI
Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF–TIMI 48 Trial
Eri Toda Kato,Robert P. Giugliano,Christian T. Ruff,Yukihiro Koretsune,Takeshi Yamashita,Róbert Gábor Kiss,Francesco Nordio,Sabina A. Murphy,Tetsuya Kimura,James Jin,Hans Lanz,Michele Mercuri,Eugene Braunwald,Elliott M. Antman +13 more
TL;DR: Age has a greater influence on major bleeding than thromboembolic risk in patients with atrial fibrillation, and treatment of elderly patients with edoxaban provides an even greater absolute reduction in safety events over warfarin, compared to treatment with Edoxaban versus warFarin in younger patients.
Journal ArticleDOI
Present Status of Anticoagulation Treatment in Japanese Patients With Atrial Fibrillation : A Report From the J-RHYTHM Registry
TL;DR: In this paper, a total of 7,937 patients with atrial fibrillation (AF) were registered from 158 institutions for the J-RHYTHM Registry.
Journal ArticleDOI
Optimal Treatment Strategy for Patients With Paroxysmal Atrial Fibrillation
Satoshi Ogawa,Takeshi Yamashita,Tsutomu Yamazaki,Yoshifusa Aizawa,Hirotsugu Atarashi,Hiroshi Inoue,Tohru Ohe,Hiroshi Ohtsu,Ken Okumura,Takao Katoh,Shiro Kamakura,Koichiro Kumagai,Yoshihisa Kurachi,Itsuo Kodama,Yukihiro Koretsune,Tetsunori Saikawa,Masayuki Sakurai,Kaoru Sugi,Toshifumi Tabuchi,Haruaki Nakaya,Toshio Nakayama,Makoto Hirai,Masahiko Fukatani,Hideo Mitamura +23 more
TL;DR: The Japanese Rhythm Management Trial for Atrial Fibrillation (J-RHYTHM) as mentioned in this paper showed that rhythm control was associated with fewer primary endpoints than rate control, and significantly fewer patients requested changes of assigned treatment strategy in the rhythm control vs the rate control group, which was accompanied by improvement in AF-specific quality of life scores.